Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Breast Cancer

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

Lancet Oncol.

Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, De Laurentiis M, Thomas G, De Placido P, Arpino G, De Placido S, Cristofanilli M, Giordano A, Puglisi F, Pistilli B, Prat A, Del Mastro L, Venturini S, Generali D

doi: 10.1016/S1470-2045(19)30420-6.

Breast Cancer

CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials

doi: 10.1007/s10549-018-4901-0.

RECOMMENDED

Breast Cancer

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis

Lancet Oncol.

Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M

doi: 10.1016/S14702045(18)30750-2.

Gynecologic Cancer

Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis

Eur J Cancer.

Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A, Kandalaft LE

doi: 10.1016/j.ejca.2020.10.014.

Breast Cancer

Breast Cancer Treatment in the Era of Precision Medicine

1Breast Cancer Center, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland

Breast Cancer

Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis

Eur J Cancer.

Raphael J, Desautels D, Pritchard KI, Petkova E, Shah PS

doi: 10.1016/j.ejca.2017.12.010.

Breast Cancer

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines

Breast Cancer Res Treat.

Drögemöller BI, Wright GEB, Shih J, Monzon JG, Gelmon KA, Ross CJD, Amstutz U, Carleton BC; CPNDS Clinical Recommendations Group

doi: 10.1007/s10549-018-5027-0.

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis

Lung Cancer.

Breadner D, Blanchette P, Shanmuganathan S, Boldt RG, Raphael J

doi: 10.1016/j.lungcan.

Related content

Recent Developments in Metastatic Breast Cancer

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis

Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis

Breast Cancer Treatment in the Era of Precision Medicine

Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines

Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis